<code id='EB5D78DF9A'></code><style id='EB5D78DF9A'></style>
    • <acronym id='EB5D78DF9A'></acronym>
      <center id='EB5D78DF9A'><center id='EB5D78DF9A'><tfoot id='EB5D78DF9A'></tfoot></center><abbr id='EB5D78DF9A'><dir id='EB5D78DF9A'><tfoot id='EB5D78DF9A'></tfoot><noframes id='EB5D78DF9A'>

    • <optgroup id='EB5D78DF9A'><strike id='EB5D78DF9A'><sup id='EB5D78DF9A'></sup></strike><code id='EB5D78DF9A'></code></optgroup>
        1. <b id='EB5D78DF9A'><label id='EB5D78DF9A'><select id='EB5D78DF9A'><dt id='EB5D78DF9A'><span id='EB5D78DF9A'></span></dt></select></label></b><u id='EB5D78DF9A'></u>
          <i id='EB5D78DF9A'><strike id='EB5D78DF9A'><tt id='EB5D78DF9A'><pre id='EB5D78DF9A'></pre></tt></strike></i>

          Home / explore / leisure time

          leisure time


          leisure time

          author:focus    Page View:84565
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In